Medical Oncology

Prostate Cancer   

Questions discussed in this category



Assuming patient received appropriate local therapy for brain metastases, which agent would you use?

What is the time window in which you would consider adding AR targeted therapy? Is there a time frame in which you would NOT consider introducing sin...

Is there an optimal strategy to minimize unnecesary steroid use?For example, pre-treatment dexamethasone or 3 day dexamethasone? Prednisone only conti...

Is there data and FDA approval for this indication? What about for nodal failure after radiation? 

How would a much higher risk cancer affect decision making? How would you treat him? 

Abstract 5014 at ASCO annual meeting 2019 showed superiority of PSMA-PET imaging over fluciclovine-PET imaging.  Are you utilizing these speciali...

In the SPARTAN trial, median PSA at study entry was ~ 7. Does the MFS benefit extend to patients with low PSA(< 2 or < 1)?

For instance, if the fluclicovine scan shows a few small avid nodes not only in the pelvis but extending to the paraaortic region, would you treat the...

Based on the RADICALS-RT trial presented at ESMO, can RT be omitted in post op prostate patients in favor of salvage RT? If not which group of patient...

In a patient with a prior response to ADT and progression on taxane and platinum chemotherapy, would you consider AR directed therapy?

Does the STAMPEDE trial, showing a survival benefit with the addition of docetaxel to standard treatment, change the standard of care for high risk, n...

A recent NCBD analysis (Rusthoven et al, JCO 2016) suggests that the addition of prostate RT significantly improves survival compared to ADT alon...

Treatment for small cell/neuroendocrine prostate is extrapolated from data on small cell lung cancer. It now appears that Carboplatin + Etoposide + At...

Are you directed by symptoms, PSA changes or do you have a standard schedule regardless of those factors?

Abstract LBA5_PR ‘Radiotherapy (RT) to the primary tumour for men with newly-diagnosed metastatic prostate cancer (PCA): survival results from S...

Prospective International Randomized Phase II Study of Low-Dose Abiteraterone with Food versus Standard Dose Abiraterone In Castration-Resistant Prost...

For which patients would you consider addition of apalutamide or enzalutamide? How do you decide between the 2 drugs?

NCCN recommends to change therapy or maintain current therapy in this setting without further clarification. What thresholds would cause a change in t...

In patients with new bone pain and without any evidence of bone metastases receiving GnRH agonists, how do you manage pain symptoms?

Two retrospective studies from Stanford showed that patients who received ADT had an increased risk of dementia and Alzheimer's. Is this finding ...

Do you use a PSA threshold, PSA doubling time, or only evidence of metastatic disease to trigger ADT? For those without rapid doubling time, do you ev...

Given recent advancements in the understanding of biological differences in prostate cancer patients of African vs. other ancestry, does your manageme...

Only the mCRPC population was included in the Fizazi et al. study, but the FDA approval is for prevention of skeletal related events from any solid tu...

If so, how do you sequence this with other therapies?  In addition, in the absence of an effect on radiographic PFS or serum PSA, how do you asse...

In situations where there is a significant risk of either local or nodal persistence/recurrence post prostatectomy with a rising PSA, or nodal involve...

A recent systematic review suggested that disease progression owing to a testosterone "flare" may not be a real phenomenon: http://www.ncbi.nlm.nih.go...

The role of adjuvant docetaxel with ADT following RT for high risk disease has been previously elucidated by RTOG 0521.  Following prostatectomy,...

At the ASCO 2016 annual meeting, results of the PRINCE trial were reported. A strategy of intermittent docetaxel was found to be non-inferior to conti...

 In a patient with node positive disease, treated definitively with radiation, should continuous or intermittent ADT be administered? If a patien...

Typically radium-223 is reserved for men with symptomatic bone disease after failure of multiple other therapies.  Is there a population of men w...

What factors should be considered with offering SBRT to oligometastatic bone disease in prostate cancer patients? Should this been done off of a proto...


Papers discussed in this category


Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-04-10

Lancet, 2016 Mar 19

Eur. Urol.,

Clinical cancer research : an official journal of the American Association for Cancer Research, 2015-09-01

Eur Urol, 2015 Jul 16

BJU Int, 2009 Feb

European urology, 2014-06

The New England journal of medicine, 2013-07-18

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-05-10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-01-20

The New England journal of medicine, 2004-10-07

JAMA oncology, 2016-11-01

J. Nucl. Med., 2015 Jun 25

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-04-01

Lancet Oncol., 2010-02-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-03-20

The Journal of urology, 2005-08

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002-08-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-06-20

The Journal of urology, 2002-09

Clinical cancer research : an official journal of the American Association for Cancer Research, 2009-01-15

Nature, 2005-12-08

J Clin Oncol, 1999 Jul

Lancet, 2015 Jan 3

The New England journal of medicine, 2001-12-06

Lancet, 2001-09-22

Breast Cancer Res. Treat., 2010-02-01

The Journal of urology, 1982-06

Cancer research, 2000-04-15

J. Clin. Oncol., 2009-04-01

Oncol. Rep., 2015-12-01

Nat Commun, 2015-04-01

PLoS ONE, 2016-01-01

J. Urol., 2002-04-01

European urology, 2018-02

Lancet, 2018 Oct 18

The Lancet. Oncology, 2006-06

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-06-20

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-02-20

JAMA oncology, 2016-04

JAMA oncology, 2017-01-01

The New England journal of medicine, 2018-04-12

The New England journal of medicine, 2018-06-28

The New England journal of medicine, 2015-08-20

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-08-20

N. Engl. J. Med., 2019 Jun 02

Nat Rev Urol, 2014 Apr

Clinical cancer research : an official journal of the American Association for Cancer Research, 2013-07-01

N Engl J Med, 2010 Jul 29

N. Engl. J. Med., 2017-07-27

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-04-10

Prostate Int,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-05-10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-05-10

Nat Rev Urol, 2017 Dec 12

The New England journal of medicine, 2017-07-27

Ann. Oncol.,

N. Engl. J. Med., 2019 May 31

J. Clin. Oncol., 2019 Jul 22

JAMA Oncol,

The Lancet. Oncology, 2019-03

BJU international, 2012-10

European urology, 2018-08

N. Engl. J. Med., 2019 Sep 30

Lancet,

Eur. Urol., 2018 Jul 03

Lancet, 2019 Apr 11

J. Clin. Oncol., 2017 Dec 14

Eur. Urol., 2019 Jul 19

Lancet, 2008 Dec 16

Lancet, 2011-12-17

J Thorac Oncol. , 2019 Oct 17

Cancer, 2020 Feb 19

Clin Genitourin Cancer, 2019 Mar 13

N. Engl. J. Med., 2020 May 29

Clinical cancer research : an official journal of the American Association for Cancer Research, 2012-12-15

,

BMC Cancer, 2014 Sep 15

JAMA Oncol,

Eur Urol, 2019 Feb 28

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-12-10